-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

623.P1.85 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I

Symposia: Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)

Andrew D. Zelenetz, MD, PhD1, Wojciech Jurczak, MD, PhD2*, Vincent Ribrag, MD3, Kim M. Linton, MBChB, PhD4*, Graham P. Collins, MBBS, MA, MRCP, FRCPath, DPhil5, Mark Bishton, PhD, MBChB6, Javier López Jiménez, MD, PhD7*, Bhagirathbhai Dholaria, MBBS8, Andrea Mengarelli, MD9*, Tycel J. Phillips, MD10, Nagendra Prasad Sungala, MBBS FRACP FRCPA11, Henry Chan12, Gerardo Musuraca, MD, PhD13*, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath14*, Junyi Yan15*, Weiming Xu, MD, PhD15*, Michel Azoulay, MD, MBA16* and Pier Luigi Zinzani, MD, PhD17

1Memorial Sloan Kettering Cancer Center, New York, NY
2Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
3Gustave Roussy Cancer Campus, Villejuif, France
4The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom
5Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, ENG, United Kingdom
6Nottingham University Hospitals, Nottingham, United Kingdom
7Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain
8Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN
9Regina Elena National Cancer Institute, Rome, ITA
10Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI
11Department of Haematology, Liverpool Hospital, Sydney, NSW, AUS
12North Shore Hospital, Auckland, New Zealand
13Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Italy
14Belfast HSC Trust, Belfast, United Kingdom
15MEI Pharma, Inc., San Diego, CA
16Kyowa Kirin Co., Princeton, NJ
17Institute of Hematology “Seràgnoli” University of Bologna, Bologna, Italy

Preetesh Jain, MBBS, MD, DM, PhD1, Chi Young Ok, MD2, Ahmed Fetooh3*, Rashmi Kanagal-Shamanna, MD4, Fatima Zahra Jelloul, MD2*, Holly Hill5*, Kristen Floyd6*, Sanam Loghavi, MD2, Zhuang Zuo, MD7*, C. Cameron Yin, MD, PhD8, Mark Routbort, MD, PhD9*, Guilin Tang, MD, PhD2*, Sairah Ahmed, MD8, Luis Enrique Malpica Castillo, MD8, Asiya Siddiqui3*, Wendy Chen10*, Onyeka Oriabure5*, Maria Badillo, MSN, RN, OCN, CCRP5*, Raphael E Steiner, MD11, Swaminathan P. Iyer, MD5, Hun Ju Lee, MD5, Rajyalakshmi Luthra, PhD2*, Francisco Vega, MD, PhD2, Christopher R. Flowers, MD11, Jeffrey Medeiros, MD, PhD2*, Michael L. Wang, MD12, Keyur P. Patel, MBBS, PhD2, Nathan H. Fowler, MD8,13 and Ranjit Nair, MD14

1Department of Lymphoma and Myeloma, UTMDACC, Houston, TX
2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
3The University of Texas MD Anderson Cancer Center, Houston
4Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX
5Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
6UT MD Anderson Cancer Center, Houston
7University of Texas, MD Anderson Cancer Center, Houston, TX
8The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX
10Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, NEW YORK, NY
11Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
12MD Anderson Cancer Center, Houston, TX
13BostonGene Corporation, Waltham, MA
14Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX

Sunandini Sharma1*, Alyssa C. Bouska, Ph.D.1*, Alicia Gamboa2*, Roshia Ali, Ph.D3*, Issa Ismail Issa4*, Waseem G. Lone, Ph.D.1*, Dylan T. Jochum, BS1, Weiwei Zhang, Ph.D.1*, Salma Elhag5*, Dario Ghersi, PhD6*, Dalia ElGamal, MSc, PhD7, Julie M. Vose, MD, MBA8, Chengfeng Bi, MD, PhD3*, Akil Merchant, MD2 and Javeed Iqbal, Ph.D.1*

1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
2Cedars-Sinai Medical Center, Los Angeles, CA
3University of Nebraska Medical Center, Omaha, NE
4Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
5University of Nebraska Medical Center, Omaha
6University of Nebraska at Omaha, Omaha
7Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, NE
8Division of Hematology & Oncology, Department of Internal Medicine, University of Nebraska Medical Center - Fred and Pamela Buffett Cancer Center, Omaha, NE

Angela Ferrari, MD1*, Sara Rattotti2*, Simone Ferrero, MD3, Michele Merli, MD4*, Francesco Merli, MD1*, Sara Veronica Usai5*, Marina Deodato, MD6*, Alessandro Pulsoni7*, Emanuele Cencini, MD8*, Francesca Re, MD9*, Maria Chiara Tisi, MD10*, Marcia Torresan Delamain, MD, PhD11*, Michele Spina, MD12, Ombretta Annibali, MD, PhD13*, Angela Rago, MD14*, Carola Boccomini15*, Andrés J M Ferreri, MD16, Maria Elena Nizzoli, MD17*, Luca Arcaini18*, Stefano Luminari, MD19 and Marzia Varettoni, MD2*

1Hematology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
2Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
3Hematology 1 U, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy/AOU “Città della Salute e della Scienza di Torino”, Torino, Italy
4Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, University of Insubria, Varese, Italy
5Hematology, Ospedale Oncologico Armando Businco, Cagliari, Italy
6ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Department of Hematology, Milano, Italy
7Institute of Hematology, University La Sapienza and Hospital Umberto I, Roma, Italy
8Division of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, Italy
9Hematology and CTMO, Azienda Ospedaliera-Universitaria di Parma, Parma, Italy
10Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
11Hematology and Hemotherapy Center, University of Campinas, Campinas, Brazil
12Division of Medical Oncology and Immune-related Tumors, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy
13Unit of Hematology, Stem Cell Transplantation, University Campus Bio Medico, Rome, Italy
14UOSD Ematologia, ASL Roma 1, Rome, Italy
15Division of Hematology 2, AOU Città della Salute e della Scienza di Torino, Torino, Italy
16Lymphoma Unit, Dept of Onco-hematology, IRCCS San Raffaele Scientific Institute, Milano, Italy
17PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy
18Department of Molecular Medicine, University of Pavia, Pavia, Italy
19Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy

Paolo Strati, MD1, Beth Christian2, Peter Martin, FRCPC, MD, MS3, Becky Champion4*, Morton Coleman, MD5*, Richy Agajanian, MD6*, Sonali M. Smith, MD7, Parameswaran Venugopal, MD8, Izidore S. Lossos, MD9, Robert Kridel, MD10, Roser Calvo11*, Kara Higgins12* and Deborah M. Stephens, DO13

1The University of Texas MD Anderson Cancer Center, Houston, TX
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
3Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY
4Norton Cancer Institute, Louisville, KY
5Clinical Research Alliance/Weill Cornell Medicine, New York, NY
6The Oncology Institute of Hope & Innovation, Downey, CA
7The University of Chicago Medical Center, Chicago, IL
8Rush University Medical Center, Chicago, IL
9University of Miami - Miller School of Medicine, Miami, FL
10Princess Margaret Cancer Centre, Toronto, ON, Canada
11AstraZeneca, Gaithersburg, MD
12AstraZeneca, South San Francisco, CA
13University of Utah Huntsman Cancer Institute, Salt Lake City, UT

Lu Zhang, MD1*, Yujun Dong2*, Hongling Peng3*, Hao Li, MD4*, Mingzhi Zhang, MD, PhD5, Hui-Han Wang6*, Qinhua Liu7*, Liping Su8*, Liye Zhong9*, Wenjun Wu10*, Liang Huang, MD11, Xiaojing Yan, MD, PhD12, Lei Fan13*, Wenjiao Tang, MD14*, Zhenling Li15*, Lintao Bi16*, Yan Li17*, Guangxun Gao, MD18*, Li Gao19*, Ting-Bo Liu20*, Yongqiang Wei21*, Yao Liu22*, Yu Li23*, Hui Zhou24*, Chunyan Sun, MD25*, Wenbin Qian, MD, PhD26, Dehui Zou27*, Huilai Zhang28*, Kaiyang Ding29*, Xiaobo Wang30*, Ou Bai, MD/PhD31*, Wenrong Huang32*, Bing Chen33*, Lin Yang34*, Jia Song35*, Da Gao36*, Tong Chen, MD37, Jun Luo38*, Shuye Wang39*, Liangming Ma, MD40* and Jian Li, MD41

1Department of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Beijing, China
2Department of Hematology, Peking University First Hospital, Beijing, China
3Department of Hematology, Second Xiang-ya Hospital, Central South University, Changsha, China
4Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
5Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
6Department of Hematology, Sheng Jing Hospital of China Medical University, Shenyang, CHN
7Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
8Department of Hematology, Shanxi Cancer Hospital, Taiyuan, China
9Department of Hematology, Guangdong Provincial People’s Hospital/Guangdong Academy of Medical Sciences, Guangzhou, China
10Bone Marrow Transplantation Center, The First Affiliated Hospital of Zhejiang Medical College, Zhejiang University, Hangzhou, China
11Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12Department of Hematology, First Hospital of China Medical University, Shenyang, China
13Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China
14Department of Hematology, Institute of Hematology, West China Hospital Sichuan University, Chengdu, China
15Department of Hematology, China-Japan Friendship Hospital, Beijing, China
16Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, China
17Department of Hematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, CHN
18Department of Hematology, Xijing Hospital, Xi'An, China
19Department of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China
20Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, CHN
21Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
22Department of Hematology, Chongqing Cancer Hospital, Chongqing, China
23Department of Hematopathology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
24Department of Lymphoma & Hematology, Hunan Cancer Hospital/The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, China
25Union Hospital,Tongji Medical College,Huazhong University of Science and Technology, Wuhan, China
26Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
27State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
28Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
29Department of Hematology, The First Affiliated Hospital of USTC, Hefei, CHN
30Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, CHN
31Department of Hematology, The First Hospital of Jilin University, Changchun, China
32Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
33Department of Hematology, Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing, China
34Department of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, CHN
35Department of Hematology, General Hospital of Tianjin Medical University, Tianjin, China
36Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
37Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China
38Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China
39Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, China
40Department of Hematology, Shanxi Bethune Hospital, Taiyuan, China
41Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Tine Bennedsen1*, Mikkel Simonsen2*, Peter de Nully Brown, MD, PhD3*, Michael Roost Clausen, MD, PhD4*, Andriette Dessau-Arp, MD5*, Judit Jørgensen, MD, PhD6*, Thomas S. Larsen, MD, PhD7*, Christian Bjørn Poulsen, MD8*, Lasse Hjort Jakobsen, MSc, PhD1* and Tarec Christoffer Christoffer El-Galaly, MD, DSc9

1Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
2Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
3Department of Haematology, Rigshospitalet, Copenhagen, Denmark
4Department of Haematology, Vejle Hospital, Vejle, Denmark
5Department of Haematology, South West Jutland Hospital, Esbjerg, Denmark
6Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
7Department of Hematology, Odense University Hospital, Odense, Denmark
8Department of Haematology, Zealand University Hospital, Roskilde, Denmark
9Aalborg University Hospital, Aalborg, Denmark

Takashi Watanabe, MD, PhD1,2*, Kensei Tobinai, MD1, Masashi Wakabayashi, MSc3*, Dai Maruyama, MD, PhD1, Kazuhito Yamamoto, MD, PhD4, Nobuko Kubota, MD, PhD5*, Kazuyuki Shimada6, Kohsuke Asagoe, MD, PhD7*, Motoko Yamaguchi, MD, PhD8, Kiyoshi Ando, MD, PhD9, Michinori Ogura, MD, PhD10, Junya Kuroda, MD, PhD11, Youko Suehiro, MD, PhD12*, Yoshihiro Matsuno, MD, PhD13*, Kunihiro Tsukasaki, MD, PhD14 and Hirokazu Nagai, MD, PhD15

1Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
2Department of Personalized Control Science of Myeloid and Lymphoid Tumors, Mie University Graduate School of Medicine, Tsu, Japan
3JCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan
4Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan
5Department of Hematology, Saitama Cancer Center, Saitama, Japan
6Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
7Department of Hematology and Oncology, Shiga General Hospital, Moriyama, Japan
8Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
9Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
10Department of Hematology and Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan
11Division of Hematology and Oncology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
12Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
13Department of Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
14Department of Hematology, International Medical Center, Saitama Medical University, Saitama, Japan
15Department of Hematology and Oncology Research, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan

Mariana Bastos-Oreiro, MD, PhD1*, Antonio Gutierrez, MD, PhD2*, Almudena Cabero Martínez3*, Javier López Jiménez, MD, PhD4*, Paola Sandra Villafuerte Gutierrez, MD5*, Ana Jimenez-Ubieto, MD, PhD6*, Adolfo De La Fuente, MD7*, Belén Navarro, MD8*, Maria Stefania Infante, MD9*, Raul Cordoba, MD, PhD10, Jaime Perez De Oteyza, MD, PhD11, Sonia González de Villambrosia, MD12*, Raquel Del Campo13*, Daniel Garcia14*, Antonio Salar, MD, PhD15* and Juan-Manuel Sancho, MD, PhD16*

1Servicio de Hematología y Hemoterapia, Hospital Gral. Univ. Gregorio Marañón, Madrid, Madrid, Spain
2Hematology Department, Hospital Universitario Son Dureta, Palma, Spain
3Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain
4Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain
5Hematology and hemotherapy department, Hospital Universitario Príncipe de Asturias, Alcala De Henares, Spain
6Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
7MD Anderson Cancer Center, Madrid, ESP
8Hematology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain
9Hematology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
10Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-JDF, Madrid, Spain
11Hospital Universitario Madrid Sanchinarro, Madrid, Spain
12Hospital Universitario Marqués de Valdecilla, Santander, Spain
13Hematology Department, Hospital Son Llàtzer, Palma, Spain
14Hematology Department, Hospital Sanitas La Zarzuela, Madrid, Spain
15Department of Hematology, Hospital del Mar, Barcelona, ., Spain
16Clinical Hematology Department, Hospital Germans Trias i Pujol, Badalona, Spain

Tove Wästerlid, MD, PhD1,2*, Anna Warnqvist3*, Caroline E. Weibull, MSc, PhD4*, Björn E Wahlin, MD, PhD5,6, P-O Andersson, MD, PhD7*, Gunilla Enblad, MD, PhD8,9*, Eva Kimby, MD, PhD10 and Karin Ekstroem Smedby, MD, PhD11,12*

1Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
2Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden
3Biostatistics Division, Department of Environmental Medicine, Karolinska Institutet, Stockholm, SWE
4Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
5Karolinska Institutet, Department of Medicine, Huddinge, Stockholm, Sweden
6Dept of Hematology, Karolinska University Hospital, Solna, Sweden
7Department of Hematology, Borås Hospital, Gothenburg, Gothenburg, Sweden
8Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
9Dept of Oncology, Akademiska University Hospital, Uppsala, Sweden
10Hematology, Karolinska Institute, Stockholm, Sweden
11Department of Hematology, Karolinska University Hospital, Solna, Sweden
12Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Stockholm, Sweden

Carla Hajj, MD1*, Emily S. Lebow, MD1*, Jisun Lee1*, Beatrice Fregonese, MPH2*, N. Ari Wijetunga, MD, PhD3*, Harper Hubbeling, MD1, Kathryn R. Tringale, MD, MAS1*, Morgan E. Freret, MD, PhD1*, Brandon S. Imber, MD1 and Joachim Yahalom, MD1

1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
2Memorial Sloan Kettering Cancer Center, New York City, NY
3Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

Jaimal Kothari1*, Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD1*, Ali Rismani2*, Helen McCarthy, MBBS FRCP PhD FRCPath3*, Angela Collins, MBBS4*, David John Lewis, MBChB, PhD5*, Suzanne O Arulogun, MBBS, FRACP, FRCPA6, William Wilson7*, Laura Clifton-Hadley, BSc, PhD8*, Darren Edwards9*, Kushani Ediriwickrema7*, Rebecca Auer, MRCP, FRPath, PhD10*, Guy Pratt, MD FRCP FRCPath11*, Ruth M. de Tute12*, Roger G Owen12* and Shirley D'Sa13,14*

1Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
2University College London Hospital, UCLH Centre for Waldenström and Related Conditions, London, United Kingdom
3The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, United Kingdom
4Haematology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
5Department of Haematology, Derriford Hospital, Plymouth, United Kingdom
6University College London Hospitals NHS Foundation Trust, London, United Kingdom
7Cancer Research UK and UCL Cancer Trials Centre University College London, London, United Kingdom
8Cancer Research UK & UCL Cancer Trials Centre, University College London, London, United Kingdom
9Cancer Research UK Clinical Trials Unit, University College London Cancer Trials Centre, London, United Kingdom
10Bartholomew’s Hospital, Barts Health NHS Trust, London, United Kingdom
11Queen Elizabeth Hospital Birmingham, WMRC, Birmingham, United Kingdom
12HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
13Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom
14Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

Kamel Laribi, MD1*, Stéphanie Poulain, MD, PhD2*, Lise Willems, MD3*, Fatiha Merabet, MD4*, Charles Herbaux5, Damien Roos Weil, MD, PhD6*, Alix Baugier de Materre, MD7*, Xavier Roussel, MD8*, Sabine Tricot, MD9*, Jehan Dupuis, MD10*, Ronan Le Calloch, MD11*, Benoit Bareau, MD12*, Marie C Béné, PharmSciD, PhD13* and Veronique Leblond, MD, PhD14

1Department of Hematogy, Centre Hospitalier Le Mans, Le Mans, France
2Service d'Hématologie Cellulaire, Centre de Biologie et Pathologie, CHRU de Lille, France/ INSERM UMR-S 1172, IRCL, Lille, FRA
3Cochin Hospital - Assistance Publique Hôpitaux de Paris, Paris, France
4Department of Hematology, CH Versailles, Le Chesnay, France
5Hematology Department, Montpellier University Hospital, Montpellier, France, Montpellier, France
6Hematology department, Sorbonne Université Hôpital Pitié Salpêtrière APHP, Paris, FRA
7CLINEA CRF Port Royal, Paris, France
8Centre Hospitalier Universitaire Besancon, Besancon, FRA
9Service d'Hématologie Clinique, CH de Valenciennes, Valenciennes, France
10Lymphoid Malignancies Department, Henri Mondor University Hospital, Créteil, France
11Hematology Department, General Hospital, Quimper, France
12Service d'Hématologie et Médecine interne, Hôpital Privé Sévigné, Vivalto Santé, Cesson-Sévigné, France
13Biology Department, Nantes University Hospital, Nantes, France
14Sorbonne University, Hôpital Pitié Salpêtrière, Paris, France

Jonathan Moss1*, Dirk Garmann2*, Rupert Austin1*, Florian Hiemeyer2*, Matthew J. Matasar, MD, MS3, Pier Luigi Zinzani, MD, PhD4,5, Vita Beckert2*, Lidia Mongay Soler6*, Barrett H. Childs6 and Peter N. Morcos6*

1Bast Inc Limited, Leicester, United Kingdom
2Bayer AG, Berlin, Germany
3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
4Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy
5Istituto di Ematologia “Seràgnoli”, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
6Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ

Supriya Gupta, MD1*, Christopher Graham, MD2 and Philip A Haddad, MD3

1Louisiana State University Health Sciences Centre, Shreveport, LA
2Louisiana State University Health Science Center-Shreveport, Shreveport, LA
3LSUHSC-S/Overton Brooks VAMC, Shreveport, LA

Alexey V Danilov, MD1, Alexandra Muir, BSN, RN2*, Ivana Melgar3*, Sandrine Puverel, PhD4*, Peter Sportelli, BS5, Hari P. Miskin, MSc6, Lu Chen, PhD7* and Geoffrey Shouse, PhD, DO8

1City of Hope, La Canada Flintridge, CA
2City of Hope National Medical Center, DUARTE, CA
3City of Hope, Duarte
4City of Hope, Duarte, CA
5TG Therapeutics, Inc., North Andover, MA
6TG Therapeutics, Inc., New York, NY
7Department of Information Sciences, City of Hope, Duarte
8Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA

Kurt S. Bantilan, MPH1*, Kayleigh Rutherford, MS2*, Joseph McCarter, PhD2*, Noushin Farnoud, PhD2*, Juan E. Arango-Ossa3*, Elli Papaemmanuil, PhD4 and Andrew D. Zelenetz, MD, PhD5

1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
3Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
4Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, NEW YORK, NY
5Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York

Antonio Pinto1*, Emanuele Guardalben2*, Marco Caltagirone2*, Chiara Piparo2*, Caterina Patti3*, Elsa Pennese4*, Sonya De Lorenzo5*, Vincenzo Pavone6*, Ugo Consoli7*, Francesco Piazza, MD8,9, Monia Capponi10*, Benedetta Puccini, MD11*, Luca Baldini, MD12,13*, Alessandro Pulsoni14*, Stefan Hohaus15*, Piero Maria Stefani16*, Simone Santini17*, Vittorio Ruggero Zilioli, MD18*, Caterina Stelitano19*, Luca Arcaini, MD20,21*, Giuseppe Gritti22*, Marco Ladetto, MD23,24 and Pier Luigi Zinzani, MD, PhD25,26

1Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology and Innovative Therapies, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, 80131, Italy
2Roche S.p.A., Monza, Italy
3Division of Onco-Hematology, Azienda Villa Sofia Cervello, Palermo, Italy
4Lymphoma Unit, Department of Hematology, Ospedale Spirito Santo, Pescara, Italy
5Hematology and Bone Marrow Transplantation, A.O.R.N. “S. G. Moscati”, Avellino, ITA
6Hematology, "Card. G. Panico" Hospital, Tricase, Italy
7A.O.R.N. Garibaldi, Catania, Italy
8University of Padova, Padova, Italy
9Azienda Ospedaliera Universitaria di Padova, Padua, Italy
10Institute of Hematology, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy
11Careggi University Hospital, Firenze, Italy
12University of Milan, Milan, Italy
13Hematology & BMT Unit, Fondazione IRCCS Ospedale Maggiore Policlinico di Milano, University of Milan, Milan, Italy
14Sapienza University of Rome, Rome, Italy
15University Policlinico Gemelli Foundation, IRCCS, Catholic University of the Sacred Heart, Roma, Italy
16Hematology Unit, General Hospital Ca' Foncello, Treviso, ITA
17ASL Toscana Centro, Prato, ITA
18Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, IT-MI, Italy
19Grande Ospedale Metropolitano, Reggio Calabria, RC, ITA
20University of Pavia, Pavia, Italy
21Division of Hematology and Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
22Ospedale Papa Giovanni XXIII, Bergamo, ITA
23Università del Piemonte Orientale, Alessandria, Italy
24Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, ITA
25IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli”Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy
26Institute of Hematology "Seràgnoli" University of Bologna, Bologna, Italy

Roxanna Seyedin, PhD1*, Ken Hasegawa, PhD2*, Krithika Rajagopalan, PhD1* and Sally W Wade, MPH3*

1Anlitiks Inc., Dover, MA
2Kite, A Gilead Company, Santa Monica, CA
3Wade Outcomes Research and Consulting, Salt Lake City, UT

Kaitlin Annunzio, DO1, Natalie S. Grover, MD2, Rui Li, MPH3*, Daniel Jones, MD, PhD4, Walter Hanel, MD5*, Beth Christian4, Adam J. Olszewski, MD6 and Narendranath Epperla, MD, MS7

1The Ohio State University, Columbus, OH
2Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
3Division of Hematology, The Ohio State University, Columbus, OH
4The Ohio State University Comprehensive Cancer Center, Columbus, OH
5Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
6Division of Hematology/Oncology, Brown University, Providence, RI
7The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH

Priyanka Gaitonde1*, Ling Cai2*, Paulo de Miranda, MD1, Jack Roos2*, Simon Rule3* and Michael L. Wang, MD4

1AstraZeneca, Gaithersburg, MD
2AstraZeneca, South San Francisco, CA
3AstraZeneca, Mississauga, ON, Canada
4MD Anderson Cancer Center, University of Texas, Houston, TX

Jose Angel Hernandez-Rivas, MD, PhD1*, Pier Luigi Zinzani, MD, PhD2, Mats Jerkeman, MD, PhD3, Malalatiana Be Harvel4*, Suzy Van Sanden5*, Joris Diels, MSc5*, Asad Husain, BSc, MBA6*, Christoph Tapprich, MD7*, Sanjay Deshpande8*, Steven Le Gouill, MD, PhD9,10 and Martin Dreyling, MD11

1Department of Hematology, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain
2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli”Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy
3Skane University Hospital and Lund University, Lund, Skaane Laen, Sweden
4Janssen Health Economics & Market Access EMEA, High Wycombe, United Kingdom
5Janssen Health Economics & Market Access EMEA Statistics & Modelling, Beerse, Belgium
6Janssen Global Market Access, Toronto, Canada
7Janssen EMEA Medical Affairs, Neuss, Germany
8Janssen Global Medical Affairs, Raritan, NJ
9Institut Curie Comprehensive Cancer Center, Paris, France
10Hospitalier Universitaire de Nantes, Centre de Recherche en Cancérologie et Immunologie Nantes Angers, INSERM, Université de Nantes, Nantes, France
11Klinikum der Universität München, LMU, Munich, Germany

Junyuan Qi1*, Mingyuan Sun1*, Dongmei Ji2*, Ping Zhou3*, Shuning Xing3*, Cheng Huang3*, Qiying Lu3*, Wenzhi Tian3* and Lugui Qiu4

1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
2Department of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai, China
3ImmuneOnco Biopharmaceuticals(Shanghai) Inc., Shanghai, China
4Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Jahanzaib Khwaja1*, Simon Salter2*, Aisha S Patel3*, Robert Baker2*, Rajeev Gupta4*, Ali Rismani5*, Charalampia Kyriakou5, Ashutosh D. Wechalekar, MD6, Josephine M.I. Vos7,8* and Shirley D'Sa1*

1Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom
2Health Services Laboratories, London, United Kingdom
3University College London Hospital, London, ENG, United Kingdom
4University College London Hospital, London, United Kingdom
5Department of Haematology, University College London Hospital, London, United Kingdom
6Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
7Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
8Department of Immunohematology Diagnostics, Sanquin, Amsterdam, The Netherlands, Amsterdam, Netherlands

Mazyar Shadman, MD1, Ian W. Flinn, MD PhD2, Edwin C. Kingsley, MD3, Benjamin Freeman, MD4*, Moshe Yair Levy, MD5, Houston Holmes, MD, MBA5*, Charles M. Farber, MD PhD6, Arvind Chaudhry7*, Rocco Crescenzo8*, Adam Idoine8*, Xiaoping Zhang, MD8*, Aileen Cohen8*, Kunthel By, MD8*, Jane Huang, MD8* and Jeff P. Sharman, MD9

1University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
2Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
3Comprehensive Cancer Centers of Nevada, Las Vegas, NV
4Summit Medical Group, Florham Park, NJ
5Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
6Atlantic Hematology Oncology, Morristown Medical Center, Morristown, NJ
7Summit Cancer Centers, Spokane Valley, WA
8BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA
9Willamette Valley Cancer Institute & Research Center, Eugene, OR

Sarah F. McGough1*, Natasha Shamas1*, Jue Wang1*, Mahmoud Jaber2*, Binay Swarup2*, Marie-Helene Blanchet Zumofen2*, Bertrand Lautié2*, Joana Parreira2*, Michael C. Wei1 and Ashwini Shewade1*

1Genentech, Inc., South San Francisco, CA
2F. Hoffmann-La Roche Ltd, Basel, Switzerland

Vibeke Vergote1*, Sylvia Snauwaert, MD, PhD2*, Kirsten Saevels, MD3, Birgit De Beleyr4*, Marjolein Lahaye5*, Ariane Maes4*, Hilde Demuynck6*, Sarah Debussche7* and Marc Andre, MD8*

1Department of Hematology, University Hospitals Leuven, Leuven, Belgium
2Department of Hematology, AZ Sint-Jan Brugge, Brugge, Belgium
3Division of Hematology, Antwerp University Hospital, Antwerp, Belgium
4Janssen-Cilag NV, Beerse, Belgium
5Janssen-Cilag BV, Breda, Netherlands
6Center for Human Genetics, Katholieke Universiteit Leuven, Leuven, Belgium
7Department of Onco-Hematology, AZ Maria Middelares, Gent, Belgium
8Department of Hematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

Takayuki Ishikawa1, Masahiro Takeuchi2*, Kazuyuki Shimada3, Kohmei Kubo4*, Takeshi Kondo5, Katsuya Fujimoto6*, Tomoaki Fujisaki7*, Koji Nagafuji8, Rika Sakai9, Shingo Kurahashi10*, Tatsuro Jo11*, Kazutaka Sunami12, Senji Kasahara13,14, Tomonori Nakazato15, Haiyi Guo16*, William Novotny16*, Chris Tankersley16*, Motohisa Takai16*, Hui Yao16*, Jinhua Zhong16*, Hongjie Zhu16* and Koji Izutsu17*

1Kobe City Medical Center General Hospital, Hyogo, Japan
2Chiba Cancer Center, Chiba, Japan
3Nagoya University Hospital, Nagoya, Japan
4Aomori Prefectural Central Hospital, Aomori, Japan
5Aiiku Hospital, Sapporo, Japan
6National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
7Matsuyama Red Cross Hospital, Matsuyama, Japan
8Kurume University Hospital, Kurume, Japan
9Kanagawa Cancer Center, Yokohama, Japan
10Toyohashi Municipal Hospital, Toyohashi, Japan
11Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan
12National Hospital Organization Okayama Medical Center, Okayama, Japan
13Gifu Pharmaceutical University, Gifu, Japan
14Gifu Municipal Hospital, Gifu, Japan
15Yokohama Municipal Citizen's Hospital, Yokohama, Japan
16BeiGene (Shanghai) Co., Ltd., Shanghai, China and BeiGene USA, Inc., San Mateo, CA
17National Cancer Center Hospital, Tokyo, Japan

*signifies non-member of ASH